L. Migliazza et al., Skeletal malformations associated with congenital diaphragmatic hernia: Experimental and human studies, J PED SURG, 34(11), 1999, pp. 1624-1629
Background/Purpose: Skeletal malformations are seen occasionally in infants
with congenital diaphragmatic hernia (CDH). This study examines whether ni
trofen, able to produce CDH in fetal rats, also induces skeletal anomalies
and, if so, whether these are similar to those seen in CDH patients.
Methods: Pregnant rats received either nitrofen (100 mg, n = 7) or no treat
ment(n = 2) on gestational day 9.5. Skeletal anatomy was studied in fetuses
recovered on day 21 after alcian blue-alizarin red staining. The charts an
d postmortem records of 117 stillborns or newborns who died of CDH were inv
estigated retrospectively for skeletal defects. The proportions of anomalie
s found in the different groups were compared.
Results: The 15 control rat fetuses were normal, whereas 57 of 90 nitrofen-
exposed animals (63%) had CDH accompanied by other malformations. Skeletal
defects limited to vertebral segmentation or identity anomalies (split vert
ebra or absent, hypoplastic, or fused ribs) were seen at low thoracic and h
igh lumbar levels in 68% of animals with CDH and in 57% of those without. D
elayed ossification of limbs was seen in treated animals. There were skelet
al malformations in 31.6% of the 117 human patients with CDH. Costovertebra
l defects (malformed, extra or defective vertebral bodies or ribs and spina
bifida) were comparably frequent in infants with syndromes and in those wi
thout them (31.2% v 17.8%, not significant), whereas limb defects were sign
ificantly more frequent in those with syndromes (56.2% v 13.9%, P < .05).
Conclusion:The nature and location of costovertebral malformations found in
both CDH patients and nitrofen-exposed rats suggest that the diaphragmatic
defect and the associated organ malformations might be caused by the same
early embryonal disturbance involving axial and para-axial mesoderm. Copyri
ght (C) 1999 by W.B. Saunders Company.